Treatment patterns and clinical outcomes in patients with lymphoma aged ≥90 years: A single‑center retrospective study

The optimal treatment strategy for malignant lymphoma in patients aged ≥90 years remains unclear. This single‑center retrospective study evaluated treatment patterns and outcomes in 14 patients aged ≥90 years diagnosed with lymphoma between January 2020 and April 2026. Clinical characteristics, treatments, adverse events, and overall survival (OS) were retrospectively analyzed. The median age was 92 years (range, 90‑95 years), and diffuse large B‑cell lymphoma was the most common subtype (57%). Initial treatments included chemotherapy (n=10), steroid monotherapy (n=3), and watchful waiting (n=1). All patients receiving combination chemotherapy required dose reductions to ≤70% of standard intensity. The curative‑intent chemotherapy group (n=8) had a median OS of 374 days, compared with 46 days in the palliative‑intent group (n=4; log‑rank P=0.00299). Grade ≥3 adverse events occurred in 90% of chemotherapy‑treated patients, with 50% developing infections. Curative‑intent chemotherapy was associated with longer survival in selected patients aged ≥90 years, although treatment‑selection bias precludes causal inference. Substantial toxicity persisted despite dose reductions, emphasizing the importance of individualized treatment decisions based on functional status, comorbidities, and patient preferences.

Authors

Institutions

Publication Details

Journal
Oncology Letters
Published
2026-11-16
DOI
https://doi.org/10.3892/ol.2026.15948
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment patterns and clinical outcomes in patients with lymphoma aged ≥90 years: A single‑center retrospective study

Masayuki Kubo, Masayuki Takeda, Nozomi Okahashi, Nobuhito HARA et al.
1 links
Oncology Letters
Lymphoma Diagnosis and Treatment
article

Treatment patterns and clinical outcomes in patients with lymphoma aged ≥90 years: A single‑center retrospective study

Masayuki Kubo, Masayuki Takeda, Nozomi Okahashi, Nobuhito HARA, 星野永
article en

Abstract

The optimal treatment strategy for malignant lymphoma in patients aged ≥90 years remains unclear. This single‑center retrospective study evaluated treatment patterns and outcomes in 14 patients aged ≥90 years diagnosed with lymphoma between January 2020 and April 2026. Clinical characteristics, treatments, adverse events, and overall survival (OS) were retrospectively analyzed. The median age was 92 years (range, 90‑95 years), and diffuse large B‑cell lymphoma was the most common subtype (57%). Initial treatments included chemotherapy (n=10), steroid monotherapy (n=3), and watchful waiting (n=1). All patients receiving combination chemotherapy required dose reductions to ≤70% of standard intensity. The curative‑intent chemotherapy group (n=8) had a median OS of 374 days, compared with 46 days in the palliative‑intent group (n=4; log‑rank P=0.00299). Grade ≥3 adverse events occurred in 90% of chemotherapy‑treated patients, with 50% developing infections. Curative‑intent chemotherapy was associated with longer survival in selected patients aged ≥90 years, although treatment‑selection bias precludes causal inference. Substantial toxicity persisted despite dose reductions, emphasizing the importance of individualized treatment decisions based on functional status, comorbidities, and patient preferences.

Oncology LettersVol. 33(1)
Saiseikai Chuwa Hospital (JP), Nara Medical University (JP)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon